Schönherr Jacqueline, Seifert Philipp, Gühne Falk, Winkens Thomas, Rauchfuß Falk, Settmacher Utz, Freesmeyer Martin, Drescher Robert
Clinic of Nuclear Medicine, Jena University Hospital, 07747 Jena, Germany.
Center of Transplant Surgery, Department of General, Visceral and Vascular Surgery, Jena University Hospital, 07747 Jena, Germany.
Cancers (Basel). 2024 Jan 4;16(1):235. doi: 10.3390/cancers16010235.
We investigated transarterial radioembolization (TARE) as a palliative measure and bridging-to-transplant therapy in hepatocellular carcinoma (HCC) patients. A total of 167 patients (50 bridging, 117 palliative) with 245 TARE procedures were assessed. Fourteen patients underwent subsequent liver transplantation (LT). Patients undergoing LT exhibited significantly prolonged progression-free survival (PFS) compared to those with bridging-without-transplant ( = 0.033). No significant differences were observed between patients with bridging-without-transplant and palliative cases ( = 0.116). Median overall survival (OS) post-TARE was 16.6 months, with estimated OS rates at 6/12 months of 82.0%/60.5%, respectively. Patients who underwent LT demonstrated statistically significantly longer OS compared to those with bridging-without-transplant ( = 0.001). No marked outcome distinctions were found between bridging-without-transplant and palliative groups. The findings underscored the superiority of LT over alternative treatments. TARE served as an important component in non-LT scenarios, allowing for subsequent therapeutic options. The study reflected the highly variable and complex situations of patients with HCC, emphasizing the need for further investigations to define an optimal multimodal approach.
我们研究了经动脉放射性栓塞（TARE）作为肝细胞癌（HCC）患者的姑息性措施和桥接至移植治疗的方法。共评估了167例患者（50例桥接，117例姑息治疗），进行了245次TARE手术。14例患者随后接受了肝移植（LT）。与未进行移植的桥接患者相比，接受LT的患者无进展生存期（PFS）显著延长（P = 0.033）。未进行移植的桥接患者与姑息治疗患者之间未观察到显著差异（P = 0.116）。TARE术后的中位总生存期（OS）为16.6个月，6/12个月时的估计OS率分别为82.0%/60.5%。与未进行移植的桥接患者相比，接受LT的患者的OS在统计学上显著更长（P = 0.001）。未进行移植的桥接组与姑息治疗组之间未发现明显的结果差异。这些发现强调了LT相对于其他治疗方法的优越性。TARE在非LT情况下是一个重要组成部分，为后续治疗提供了选择。该研究反映了HCC患者高度可变和复杂的情况，强调需要进一步研究以确定最佳的多模式治疗方法。
